Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2012 3
2013 2
2014 9
2015 21
2016 62
2017 69
2018 88
2019 70
2020 66
2021 63
2022 38
2023 19
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

440 results

Results by year

Filters applied: . Clear all
Page 1
Grazoprevir.
[No authors listed] [No authors listed] 2023 Sep 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2023 Sep 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 29999878 Free Books & Documents. Review.
Grazoprevir has not been studied in nursing mothers being treated for hepatitis C infection. Because it is greater than 98.9% bound to maternal plasma proteins, amounts in breastmilk are likely to be very low. Some sources recommend against breastfeeding when grazoprevi …
Grazoprevir has not been studied in nursing mothers being treated for hepatitis C infection. Because it is greater than 98.9% bound t …
Elbasvir/grazoprevir.
[No authors listed] [No authors listed] Aust Prescr. 2017 Feb;40(1):32-34. doi: 10.18773/austprescr.2017.010. Epub 2017 Feb 1. Aust Prescr. 2017. PMID: 28246435 Free PMC article. Review. No abstract available.
Elbasvir and grazoprevir for the treatment of hepatitis C.
Wang SJ, Huang CF, Yu ML. Wang SJ, et al. Expert Rev Anti Infect Ther. 2021 Sep;19(9):1071-1081. doi: 10.1080/14787210.2021.1874351. Epub 2021 Jan 17. Expert Rev Anti Infect Ther. 2021. PMID: 33428488 Review.
DAAs can achieve a sustained virological response rate >95% in different populations.Area covered: This review summarizes the pharmacokinetics, pharmacodynamics, efficacy, and safety of Elbasvir/Grazoprevir (EBR/GZR).Expert opinion: EBR/GZR is a combination of NS5A and …
DAAs can achieve a sustained virological response rate >95% in different populations.Area covered: This review summarizes the pharmacokin …
Elbasvir-grazoprevir: A new direct-acting antiviral combination for hepatitis C.
Karaoui LR, Mansour H, Chahine EB. Karaoui LR, et al. Am J Health Syst Pharm. 2017 Oct 1;74(19):1533-1540. doi: 10.2146/ajhp160558. Am J Health Syst Pharm. 2017. PMID: 28947524 Review.
In Phase II and III clinical trials, elbasvir-grazoprevir administered orally for 12 weeks was shown to achieve a high sustained virological response 12 weeks after the end of treatment. Elbasvir-grazoprevir is a once-daily, fixed-dose combination tablet that can be …
In Phase II and III clinical trials, elbasvir-grazoprevir administered orally for 12 weeks was shown to achieve a high sustained viro …
Elbasvir/Grazoprevir: First Global Approval.
Keating GM. Keating GM. Drugs. 2016 Apr;76(5):617-24. doi: 10.1007/s40265-016-0558-3. Drugs. 2016. PMID: 26943930 Review.
A fixed-dose combination tablet of the hepatitis C virus (HCV) NS5A inhibitor elbasvir and the HCV NS3/4A protease inhibitor grazoprevir (elbasvir/grazoprevir; Zepatier) is under development by Merck. Oral elbasvir/grazoprevir 50/100 mg once daily has been ap …
A fixed-dose combination tablet of the hepatitis C virus (HCV) NS5A inhibitor elbasvir and the HCV NS3/4A protease inhibitor grazoprevir …
Elbasvir/Grazoprevir: A Review in Chronic HCV Genotypes 1 and 4.
Al-Salama ZT, Deeks ED. Al-Salama ZT, et al. Drugs. 2017 May;77(8):911-921. doi: 10.1007/s40265-017-0739-8. Drugs. 2017. PMID: 28417245 Review.
A fixed-dose combination tablet comprising the hepatitis C virus (HCV) NS5A inhibitor elbasvir and the HCV NS3/4A protease inhibitor grazoprevir (elbasvir/grazoprevir; Zepatier) was recently approved for the treatment of chronic HCV genotype 1 and 4 infection in the …
A fixed-dose combination tablet comprising the hepatitis C virus (HCV) NS5A inhibitor elbasvir and the HCV NS3/4A protease inhibitor graz …
Elbasvir/Grazoprevir.
Cada DJ, Kim AP, Baker DE. Cada DJ, et al. Hosp Pharm. 2016 Sep;51(8):665-686. doi: 10.1310/hpj5108-665. Hosp Pharm. 2016. PMID: 27698508 Free PMC article.
Grazoprevir/elbasvir for the treatment of adults with chronic hepatitis C: a short review on the clinical evidence and place in therapy.
Sulejmani N, Jafri SM. Sulejmani N, et al. Hepat Med. 2018 May 4;10:33-42. doi: 10.2147/HMER.S130103. eCollection 2018. Hepat Med. 2018. PMID: 29765256 Free PMC article. Review.
Data have shown a high barrier to resistance despite the presence of resistance-associated substitutions. Grazoprevir/elbasvir represents a very promising regimen for treatment of HCV infection. This review provides a summary of pharmacology, efficacy, and safety of gra …
Data have shown a high barrier to resistance despite the presence of resistance-associated substitutions. Grazoprevir/elbasvir repres …
Elbasvir/grazoprevir for treatment of chronic hepatitis C virus infection.
Papudesu C, Kottilil S, Bagchi S. Papudesu C, et al. Hepatol Int. 2017 Mar;11(2):152-160. doi: 10.1007/s12072-016-9761-2. Epub 2016 Sep 13. Hepatol Int. 2017. PMID: 27624503 Review.
Successful treatment for hepatitis C virus (HCV) has rapidly evolved in recent years to a well-tolerated, highly efficacious all-oral therapy. Elbasvir/grazoprevir (Zepatier) is the newest of the oral combinations of HCV direct-acting agents that was approved by the US Fed …
Successful treatment for hepatitis C virus (HCV) has rapidly evolved in recent years to a well-tolerated, highly efficacious all-oral therap …
Grazoprevir/elbasvir combination therapy for HCV infection.
Vallet-Pichard A, Pol S. Vallet-Pichard A, et al. Therap Adv Gastroenterol. 2017 Jan;10(1):155-167. doi: 10.1177/1756283X16671293. Epub 2016 Oct 17. Therap Adv Gastroenterol. 2017. PMID: 28286567 Free PMC article. Review.
Zepatier is a fixed-dose combination product coformulating MK-5172 [grazoprevir (GZR), 100 mg QD] and MK-8742 [elbasvir or (EBR) 50 mg QD]: it combines highly potent inhibitors of the HCV NS3/4A protease and NS5A replication complex, respectively. ...
Zepatier is a fixed-dose combination product coformulating MK-5172 [grazoprevir (GZR), 100 mg QD] and MK-8742 [elbasvir or (EBR) 50 m …
440 results

Searches related to "grazoprevir"